Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism ANGPTL3 inhibitors(Angiopoietin like 3 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Homozygous familial hypercholesterolemia | Phase 2 | - | 24 Sep 2023 | |
Hyperlipoproteinemia Type II | Phase 2 | CN | 17 Aug 2023 | |
Hyperlipoproteinemia Type II | Phase 2 | CN | 17 Aug 2023 |
NCT05432544 (NEWS) Manual | Phase 1 | - | (moniyjzfsh) = 300mg及以上剂量水平的LDL-C降低超过30%,持续64天以上,最高达49.1%。 pgzdgtdbye (ovwfrudahm ) View more | Positive | 06 Sep 2024 |